EFFICACY OF OLMESARTAN, IRBESARTAN AND TELMISARTAN AGAINST ACUTE INDOMETHACIN-INDUCED GASTRIC ULCERS IN MICE

Sara Khallouf 1*, Rana Makhous 1 and Rana Issa 2

1Pharmacology & Toxicology Department, Faculty of Pharmacy, Tishreen University, Lattakia, Syria
2Pathology Department, Faculty of Medicine, Tishreen University, Lattakia, Syria

Recent studies have determined detrimental effects of angiotensin-II in gastric mucosa. This study aims to investigate the gastroprotective role of some Angiotensin-II receptor blockers (ARBs): olmesartan, irbesartan and telmisartan on indomethacin-induced gastric ulcers in mice. Also, it provides a new comparison to know if the agonist action of peroxisome proliferator-activated receptor gamma (PPAR-γ) involves in protecting gastric mucosa; if found. Animals were divided into six groups (n=9 in each); group 1 (normal control), group 2 (non-pretreated, induced-ulcer), group 3 (olmesartan 8.2 mg/kg), group 4 (irbesartan 61.5 mg/kg), group 5 (telmisartan 16.4 mg/kg), group 6 (ranitidine 61.5 mg/kg). Drugs were given orally for 15 days; then gastric ulcers were induced by a single oral dose of indomethacin (250 mg/kg). Histological findings showed that these members of ARBs decreased the depth of ulcers but without significant difference between them. Their gastroprotective effects were not comparable to ranitidine effect. We need further researches, and recommend studying the effect of ARBs in combination with anti-ulcer drugs.

Keywords: angiotensin-II; gastroprotective; ARBs; PPAR-γ; gastric ulcers; indomethacin

INTRODUCTION

Peptic ulcer, whether gastric or duodenal, is a common disease affecting about 5-10% of people in the world. It occurs when the balance between defensive and aggressive factors is disturbed. It is described as a gastric mucosal erosions that are extended through the muscularis mucosa.

Angiotensin-II is the main product of renin-angiotensin system. It has crucial effects in regulating blood pressure and controlling of fluids and electrolytes in the body.

Angiotensin-II is the main product of renin-angiotensin system. It has crucial effects in regulating blood pressure and controlling of fluids and electrolytes in the body.

Recently, high concentrations of renin and angiotensin-II were observed in ulcerated gastric tissues of rats. Also, many researchers reported that angiotensin-II has detrimental effects in gastric mucosa. It reduces blood flow and induces inflammatory cascades and oxidative stress. This suggests a possible role of angiotensin-II in the pathogenesis of gastric ulcers.

Angiotensin-II receptor blockers (ARBs) are antihypertensive drugs that selectively act by blocking AT1 receptors. These drugs possess partial peroxisome proliferator-activated receptor gamma (PPAR-γ) agonistic actions. These properties vary between ARBs depending on lipophilicity. Many studies have indicated a benefit of these drugs in prevention of gastric ulcers. They suggested a difference in the gastroprotective role of ARBs, and it was attributed to PPAR-γ agonist actions.

This study aims to investigate the efficacy of these drugs in prevention of indomethacin-induced gastric ulcers in mice. Also, it provides new comparison between three members of ARBs: telmisartan (the highest partial PPAR-γ agonist), irbesartan (a less potent PPAR-γ agonist) and olmesartan (the least potent PPAR-γ agonist). This helps to know the role of agonist action of PPAR-γ in protecting gastric mucosa. Therefore, we can determine
the best drug for patients who have high blood pressure with gastric ulcers.

MATERIALS AND METHODS

Drugs

Telmisartan, irbesartan, olmesartan, ranitidine and indomethacin were obtained from Syrian pharmaceutical factories. Indomethacin was suspended in 1% aqueous solution of carboxymethyl cellulose (CMC). Other drugs were dissolved in 0.5% aqueous solution of CMC. All solutions were prepared freshly.

Animals

This experiment was carried out using 54 Balb/c male mice weighing between 20-30 g. The mice were purchased from the Scientific Research Center, Damascus, Syria. They were acclimatized for two weeks before starting the experiment. The animals were kept at controlled environmental conditions (temperature 25 ± 2 °C, humidity 50 ± 15%, under a 12 hrs. light/dark cycle). They had free access to standard mice diet and water. All methods performed in this study were in accordance with the regulatory guidance of the care and use of experimental animals. The Scientific Research Ethics Committee at Tishreen University gave us the ethical approval for this study, after reviewing all stages of work.

Experimental protocol

Animals were divided into six groups (n=9 in each group).

- **Group 1.** (normal group): received oral vehicle (CMC 0.5% solution).
- **Group 2.** (indomethacin group): received oral vehicle (CMC 0.5% solution).
- **Group 3.** (olmesartan group): received olmesartan (8.2 mg/kg).
- **Group 4.** (irbesartan group): received irbesartan (61.5 mg/kg).
- **Group 5.** (telmisartan group): received telmisartan (16.4 mg/kg).
- **Group 6.** (ranitidine group): received ranitidine (61.5 mg/kg).

Drugs and vehicle were given orally daily for 15 days. The doses were calculated depending on Human Equivalent Dose (HED)

Ulcer induction and gastric tissue collection

After 15 days, the mice were fasted from food with free access to drinking water for 16 hrs. All mice were given indomethacin in a single oral dose (250 mg/kg), except for the first group which was given an equivalent amount of CMC 1%. The dose of indomethacin was tested before starting work. It was consistent with that used by Timoshin et al.

All experiments were performed during the same time of the day to avoid diurnal variations of the putative regulators of gastric functions. The mice were sacrificed 6 hrs following indomethacin administration by an overdose of ether. Each stomach was removed and opened along the greater curvature. The stomachs were washed with saline solution, then were fixed in formalin 10% solution for histopathological examination.

![Fig. 1 : Macroscopic morphology changes in the gastric mucosa. A, normal group; B, indo group; C, olme-pretreated group; D, irbe-pretreated group; E, telmi-pretreated group; F, rani-pretreated group.](image-url)
Histopathological examination of gastric tissue

Formalin-fixed tissues were dehydrated in ascending grades of alcohol and embedded in paraffin. Sections of 5-μm thickness taken, stained with hematoxylin and eosin (H&E) and examined by light microscopy by a pathologist unaware of the treatment protocol. The ulcers were scored for intensity on a scale of 0-4 (Table 1).

Table 1: scoring system

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>normal gastric mucosa</td>
</tr>
<tr>
<td>1</td>
<td>superficial erosions of mucosa</td>
</tr>
<tr>
<td>2</td>
<td>medium depth lesions of mucosa</td>
</tr>
<tr>
<td>3</td>
<td>deep lesions of mucosa without crossing muscularis mucosa</td>
</tr>
<tr>
<td>4</td>
<td>ulcers which are extended through muscularis mucosa</td>
</tr>
<tr>
<td></td>
<td>normal gastric mucosa</td>
</tr>
</tbody>
</table>

- **Ulcer Index & Protective Ratio**

Gastric mucosal lesions were expressed in terms of the ulcer index according to the method of Desai et al.\(^6\). The ulcer index (UI) was calculated from the equation:

\[
\text{Ulcer Index (UI)} = \text{mean of intensity in a group} + \left[ \frac{\text{number of ulcer positive animals}}{\text{total number of animals}} \right] \times 2
\]

The percentage protective ratio was calculated from the equation\(^7\):

\[
\text{Protective ratio} = \left[ 1 - \frac{\text{UI pretreated group}}{\text{UI indo group}} \right] \times 100
\]

Statistical analysis

Data analyses were performed using SPSS software package (version 26). Data were presented as means ± SD. Different groups were compared using one-way analysis of variance (ANOVA) followed by the Least Significant Difference (LSD) test and Dunnett’s test for multiple comparisons. P<0.05 was selected as the criterion for statistical significance.

RESULTS AND DISCUSSION

Results

Histopathological study

In normal group, we observed some congestion of blood vessels, but the gastric epithelium was normal without any erosions (Fig. 1 A). The administration of indomethacin caused deep ulcers which were extended through muscularis mucosa. Also, inflammatory infiltrates were noted (Fig. 1 B). The pretreatment with olmesartan, irbesartan and telmisartan reduced the depth of lesions. We observed medium depth lesions without crossing the muscularis mucosa. Some inflammatory infiltrated cells were noted (Fig. 1 C,D,E).

In ranitidine group, the mucosa was protected from ulcers. We saw very superficial erosions in the epithelium without presence of the pathological changes seen in indomethacin group (Fig. 1 F).

Fig. 1: Histological assessment of gastric tissues using H&E stain. (A) normal group showed normal mucosa without any ulcer. (B) indo group showed deep ulcers which are extended through muscularis mucosa. (C, D, E) olme, irbe, telmi groups respectively showed medium depth lesions of mucosa without extending through muscularis mucosa. (F) rani group showed superficial erosions of mucosa.
Effect of ARBs on ulcer score, ulcer index and protective ratio in indomethacin induced gastric ulcers

The pretreatment with olmesartan, irbesartan and telmisartan showed significant reduction in ulcer score when compared to indomethacin group. There were a statistically significant differences in ulcer score in olmesartan, irbesartan, and telmisartan groups when compared to rani group (P< 0.05). The ulcer score of telmisartan group was lower than those of irbesartan and olmesartan groups but without statistical significance (P> 0.05) (Error! Reference source not found., Fig. 2).

Table 2: Effect of olmesartan, irbesartan, telmisartan on indomethacin induced ulcers.

<table>
<thead>
<tr>
<th>parameter</th>
<th>Ulcer score Mean ± SD</th>
<th>Ulcer index</th>
<th>Protective ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0.00 ± 0.00</td>
<td>0.00</td>
<td>-------</td>
</tr>
<tr>
<td>Indo</td>
<td>3.89 ± 0.33 @</td>
<td>5.67</td>
<td>-------</td>
</tr>
<tr>
<td>Olme</td>
<td>2.71 ± 1.11* #</td>
<td>3.29</td>
<td>42.02 %</td>
</tr>
<tr>
<td>Irbe</td>
<td>2.67 ± 0.71* #</td>
<td>2.89</td>
<td>49.02 %</td>
</tr>
<tr>
<td>Telmi</td>
<td>2.25 ± 0.89* #</td>
<td>2.25</td>
<td>60.29 %</td>
</tr>
</tbody>
</table>
| Rani       | 1.11 ± 0.33 *         | 1.11        | %&<; <; <;  % &<;)

@P < 0.05 when compared to normal group.
*P < 0.05 when compared to indo group.
&P < 0.05 when compared to rani group.

Fig. 2: Ulcer score. @P< 0.05 compared to normal group, *P< 0.05 compared to indo group, &P<0.05 compared to rani group. Data were expressed as Mean ± SD.
Discussion

In this study, mice developed acute gastric ulcers when given a single oral dose of indomethacin and this was expected. Indomethacin is the drug of choice for experimental ulcer model induction. It is superior in this property to the other NSAIDs\textsuperscript{9,19}. Pathological mechanisms include: increasing acid secretion, decreasing mucus and bicarbonate synthesis, reducing mucosal blood flow, releasing inflammatory mediators and free radicals and direct local mechanisms\textsuperscript{19,22}. Our study showed that the pretreatment with olmesartan, irbesartan and telmisartan protected the gastric mucosa from deep ulcers formation. This was consistent with many studies which suggested a gastroprotective properties of these drugs\textsuperscript{9,12\&23\&24}.

According to previous studies, these drugs maintain blood flow to the gastric mucosa by inhibiting vasoconstriction mediated by $\text{AT}_1$\textsuperscript{25} and decreasing sympathoadrenal activation\textsuperscript{26}. Also, they suppress acid secretion by increasing NO release and decreasing phosphorylated extracellular signal-regulated kinase 1 and 2 (pERK1/2). These drugs have antioxidant and anti-inflammatory properties in gastric mucosa due to $\text{AT}_1$ blocking and PPAR-$\gamma$ stimulating\textsuperscript{9\&11\&12\&26}.

Olmesartan, irbesartan and telmisartan have variant efficacy in stimulating of PPAR-$\gamma$. A previous study suggested a gastroprotective effect of PPAR-$\gamma$ agonists\textsuperscript{27}.

However, in our study, these three drugs did not show a significant difference in their effects on gastric mucosa. Since PPAR-$\gamma$ stimulating did not make a difference, we may can say that the gastroprotective role of olmesartan, irbesartan and telmisartan is due to their primary effects as $\text{AT}_1$ receptors antagonists.

This result is in contrast with the study that suggested the superiority of telmisartan over olmesartan because it is the highest partial PPAR-$\gamma$ agonist\textsuperscript{12}. As for irbesartan, this is the first study that compare its effectiveness with telmisartan and olmesartan.

Ranitidine was used as a reference drug. We found that the protective effect of these members of ARBs was less than and not comparable to ranitidine effect.

This result, about telmisartan, is consistent with this of Suvarna \textit{et al}\textsuperscript{29}, but it contradicts the study of Mohamed \textit{et al}\textsuperscript{31}.

As for irbesartan, Nancy \textit{et. al} found that its efficacy was comparable to ranitidine effect\textsuperscript{9}, and this is inconsistent with our findings.

There is not any study that compared the gastroprotective effect of olmesartan with ranitidine and this is the first one.

Conclusion

The present findings demonstrate that pretreatment by olmesartan, irbesartan and telmisartan protected mice’s gastric mucosa against indomethacin-induced ulcers. These effects were not as ranitidine effect. Olmesartan, irbesartan and telmisartan did not show any superiority in their protective effects. This is the first study that compares the gastroprotective effects of these drugs. However, we need further researches. We recommend studying the effect of ARBs in combination with anti-ulcer drugs to investigate if there is a synergistic gastroprotective effect.

REFERENCES


6. Z. Halici, B. Polat, E. Cadirci, A. Topcu, E. Karakus, \textit{et al.}, "Inhibiting renin angiotensin system in rate limiting step by
aliskiren as a new approach for preventing indomethacin induced gastric ulcers”, *Chemico-Biological Interactions*, 258,266-275(2016).


تقييم فعالية الأولميسارتان، الإريبارتين والتيليميسارتان ضد قروحات المعدة الحادة المحدثة بالإندوميتاسين لدى الفنرaran البحث

سارة خليفة 1، رنا مخوس 1، رنا عيسى 2

قسم الأدوية والسموم، كلية الصيدلة، جامعة تشرين، اللاذقية، سوريا

قسم علم الأمراض، كلية الطب، جامعة تشرين، اللاذقية، سوريا

رصدت دراسات حديثة تأثيرات موضعية للأنجيوبينتين-2 على مستوى الجدار المخاطي المعدة، لذلك تهدف هذه الدراسة للتقصي عن فعالية بعض حاصرات مستقبلات الأنجيوبيتين (الأولميسارتان، الإريبارتين والتيليميسارتان) في الوقاية من القرحة المعدية المحرّضة بالإندوميتاسين لدى فنران التجربة. يُقدم هذا البحث أيضا مقارنة جديدة لمعرفة فيما إذا كان للعند انتشال مستقبلات peroxisome proliferator-activated receptor gamma (PPAR-γ) قسم الفنران إلى 3 مجموعات (ن=9 في كل مجموعة): مجموعة شاهدة طبيعية، مجموعة شاهدة مرضية، مجموعات عولجت مسبقًا بالأولميسارتان، الإريبارتين والتيليميسارتان على الترتيب، ومجموعة عولجت بالرانيتين كدواء مرجعي مضاد للقرحة. استمرّت المعالجة لمدة 15 يومًا عبر الفم، ثم حُرّضت القرحة بجرعة صغرى وحيدة من الإندوميتاسين (50 ملغ/كلغ).

أظهرت نتائج الفحص النسيجي أن هذه الأدوية قللت من عمق التترقات الحاسلة، لكن دون وجود فرق مهم فيما بينها، كما أن هذه الفعالية الوقائيّة لم تكن كفكيّة الرانيتين.

لا يزال هذا الموضوع بحاجة إلى المزيد من التقصي والدراسة، كما نودي بتقديم الفعل الوقائي لهذه الأدوية بالمشاركة مع الرانيتين، لربما تظهر فعالًا تآزرًا في الوقاية من القرحة الهممية.